We sought to describe their association with euglycemic diabetic ketoacidosis ... in the setting of type 1 diabetes. Here we describe 13 cases of SGLT-2 inhibitor–associated euDKA or ketosis ...

Key points A 28-year-old man with cocaine and alcohol use disorders presented to the emergency department with a 2-month history of worsening shortness of breath, orthopnea, and fatigue. His medical ...

Metformin and SGLT2 inhibitors are associated with similar rates of incident gout among patients with type 2 diabetes.

Israel: A real-world analysis has provided new insights into the kidney-protective effects of sodium-glucose cotransporter-2 ...

SGLT-2 inhibitor use vs DPP-4 inhibitor use was associated with lower incidence of epilepsy among patients with type 2 diabetes.

Sodium-glucose cotransporter 2 inhibitor use is an independent risk factor for falls in people with type 2 diabetes.

Lexicon Pharmaceuticals has reported that LX4211, an inhibitor of the sodium-dependent glucose transporter 2 (SGLT2; also known as SLC5A2), significantly improved glycaemic control in a Phase II ...

Sodium-glucose cotransporter-2 inhibitors (SGLT2i), or gliflozins, are medications used in the treatment of type 2 diabetes mellitus ... associated with euglycemic ketoacidosis (eKA), which ...

The findings underscore the need to treat heart failure with urgency and double down on clinician education, one expert says.

Preoperative use of SGLT2 inhibitors among patients with type 2 diabetes ... failure (10.1% vs 17.6%). Sensitivity and ...

Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 ...

and colleagues examined the association of SGLT2 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists with falls in patients with type 2 diabetes. The analysis included annual fall ...